Acadia Pharmaceuticals Principal Accounting Officer James Kihara sold 11,421 shares on June 26, 2026, representing 46.60% of his direct holdings. The transaction was valued at approximately $298,000 and reduced his direct ownership to 13,088 shares. The sale was executed under a pre-established Rule 10b5-1 trading plan adopted in December 2025. It occurred as Acadia shares neared a 52-week high following a positive European regulatory recommendation for its Daybue drug. The company reported first-quarter 2026 revenue of $268.1 million, up from $244.3 million a year earlier.
ACADIA Pharmaceuticals IncInsider sold 46.6% of direct holdings under a 10b5-1 plan, but shares neared 52-week high on positive EU regulatory recommendation for Daybue and revenue growth.